Patents by Inventor Mark Kagan

Mark Kagan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted bisphenyl butanoic ester derivatives as NEP inhibitors
    Patent number: 11426375
    Abstract: The present disclosure provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are defined herein. The disclosure also relates to a method for manufacturing the compounds of the disclosure, and its therapeutic uses. The present disclosure further provides pharmaceutical composition of the compounds of the disclosure and a combination of pharmacologically active agents and a compound of the disclosure.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: August 30, 2022
    Assignee: Novartis AG
    Inventors: Yongshuai Chai, Sven Erik Godtfredsen, Mark Kagan, Yugang Liu, Mahavir Prashad, Zhaoyin Wang, Saijie Zhu
  • SUBSTITUTED BISPHENYL BUTANOIC ESTER DERIVATIVES AS NEP INHIBITORS
    Publication number: 20200246295
    Abstract: The present disclosure provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are defined herein. The disclosure also relates to a method for manufacturing the compounds of the disclosure, and its therapeutic uses. The present disclosure further provides pharmaceutical composition of the compounds of the disclosure and a combination of pharmacologically active agents and a compound of the disclosure.
    Type: Application
    Filed: April 21, 2020
    Publication date: August 6, 2020
    Inventors: Yongshuai CHAI, Sven Erik GODTFREDSEN, Mark KAGAN, Yugang LIU, Mahavir PRASHAD, Zhaoyin WANG, Saijie ZHU
  • Substituted bisphenyl butanoic ester derivatives as NEP inhibitors
    Patent number: 10668035
    Abstract: The present disclosure provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are defined herein. The disclosure also relates to a method for manufacturing the compounds of the disclosure, and its therapeutic uses. The present disclosure further provides pharmaceutical composition of the compounds of the disclosure and a combination of pharmacologically active agents and a compound of the disclosure.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: June 2, 2020
    Assignee: Novartis AG
    Inventors: Yongshuai Chai, Sven Erik Godtfredsen, Mark Kagan, Yugang Liu, Mahavir Prashad, Zhaoyin Wang, Saijie Zhu
  • SUBSTITUTED BISPHENYL BUTANOIC ESTER DERIVATIVES AS NEP INHIBITORS
    Publication number: 20190240177
    Abstract: The present disclosure provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are defined herein. The disclosure also relates to a method for manufacturing the compounds of the disclosure, and its therapeutic uses. The present disclosure further provides pharmaceutical composition of the compounds of the disclosure and a combination of pharmacologically active agents and a compound of the disclosure.
    Type: Application
    Filed: April 18, 2019
    Publication date: August 8, 2019
    Inventors: Yongshuai CHAI, Sven Erik GODTFREDSEN, Mark KAGAN, Yugang LIU, Mahavir PRASHAD, Zhaoyin WANG, Saijie ZHU